About the MiTiGate Trial

  • MiTiGate is a clinical trial for people living with jaw muscle pain (otherwise known as myalgia Temporomandibular Disorder - m-TMD) and is the largest randomised controlled trial of m-TMD in the UK.

    Currently, there is no clear evidence about the best treatment, and first line therapy is self-management for at least 6 weeks.

    We are looking for people with jaw muscle pain (m-TMD) to take part in a trial of new and existing treatments.

    The trial opened to recruitment in September 2024 and is expected to end recruitment in the summer of 2026.

  • Myalgia Temporomandibular Disorder (m-TMD) affects the muscles that move the jaw, causing pain. It affects 1 in every 15 people, and impacts on daily activities such as talking, eating, and chewing.

  • Participants may be identified by a site, primary care, or self-referral.

    Participants must be 18 years old or older with m-TMD pain for 3 months or longer that is not controlled by self-management.

    For more information, please see our taking part page.

Learn More

  • Our Funding

    The trial is a non-commercial trial funded by the National Institute of Health and Care Research (NIHR) on behalf of the NHS for people suffering with jaw pain.

  • Our Sponsorship

    The trial is sponsored by The Newcastle Upon Tyne Hospitals NHS Foundation Trust.

  • Recruitment

    The trial will recruit 663 participants across the UK. The trial is currently open to recruitment and will be recruiting from various locations - more information can be found on our take part page.